Santhera Announces Intent To File Marketing Authorization Application for Leber's Hereditary Optic Neuropathy
23-Sep-2010 -
Santhera Pharmaceuticals announced that it has formally notified the European Medicines Agency of its intent to file for Leber's Hereditary Optic Neuropathy (LHON). In the recent RHODOS study, Catena® showed consistent superiority over placebo and, in particular, improved or protected visual ...
blindness
eye disease
nerve cells
+3